1. Home
  2. SACH vs GRML Comparison

SACH vs GRML Comparison

Compare SACH & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.02

Market Cap

57.5M

Sector

Real Estate

ML Signal

HOLD

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.29

Market Cap

51.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SACH
GRML
Founded
2010
N/A
Country
United States
United States
Employees
27
5
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
57.5M
51.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SACH
GRML
Price
$1.02
$0.29
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
646.0K
3.6M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
19.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$145.00
N/A
Revenue Next Year
$6.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.27
52 Week High
$1.45
$0.55

Technical Indicators

Market Signals
Indicator
SACH
GRML
Relative Strength Index (RSI) 39.60 32.24
Support Level $0.99 $0.27
Resistance Level $1.13 $0.44
Average True Range (ATR) 0.06 0.04
MACD -0.03 -0.01
Stochastic Oscillator 7.45 14.94

Price Performance

Historical Comparison
SACH
GRML

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: